← Who reports today · Health Care
Abbott Laboratories (ABT) earnings date & Q3 2026 results
Net Earnings
$920M
down 44.0% y/y
Net Sales
$13,013M
up 14.5% y/y
Operating Earnings
$1,358M
down 34.0% y/y
Next report
~ Jan 21
not announced yet
The quarter in brief
Abbott's Q3 2026 net sales rose 14.5% to $13,013 million, but GAAP net earnings fell 44.1% to $920 million. Diluted EPS dropped from $0.94 to $0.53.
Key growth driver: Revenue growth of +14% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report
- Net Earnings −44.0% — gross margin fell on higher intangible amortization from the Exact Sciences acquisition, higher costs and foreign exchange
Source
«The decrease in the third quarter and the first nine months of 2026 primarily reflects higher intangible amortization expense related to the Exact Sciences acquisition, as well as the unfavorable impact of higher costs and foreign exchange.»
Form 10-Q
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net Sales | $13,013 · +14.5% |
| Cost of products sold, excluding amortization expense | $5,628 · +10.9% |
| Amortization of intangible assets | $841 · +100% |
| Research and development | $920 · +20.1% |
| Selling, general, and administrative | $4,266 · +39.8% |
| Operating Earnings | $1,358 · −34.0% · 10.4% margin |
| Interest expense, net | $297 · +575% |
| Net foreign exchange (gain) loss | $6 · −64.7% |
| Other (income) expense, net | $164 · +9.3% |
| Earnings before taxes | $1,231 · −43.5% |
| Taxes on Earnings | $311 · −42.0% · 25.3% effective rate |
| Net Earnings | $920 · −44.0% · $0.53/sh · 7.1% margin |
Verdict: Abbott's Q3 2026 net sales rose 14.5% to $13,013 million, but GAAP net earnings fell 44.1% to $920 million. Diluted EPS dropped from $0.94 to $0.53.
Abbott narrowed its full-year 2026 adjusted diluted EPS guidance to $5.50–$5.55, keeping the midpoint, and expects comparable sales growth of about 6.0%. Q4 2026 adjusted diluted EPS guidance is $1.62–$1.67. The board declared a quarterly dividend of $0.63 per share, the 411th consecutive one.
Source and notation
Source: Abbott Laboratories press release, 8-K EX-99.1 of 10/21/2026 (SEC EDGAR).
Open as an image: Abbott Laboratories (ABT), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Abbott Laboratories (ABT) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/abt. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/abt"><img src="https://whoreportstoday.com/t/abt/img/abbott-laboratories-abt-earnings-sankey.png" alt="Abbott Laboratories (ABT) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/abt">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/abt/img/abbott-laboratories-abt-earnings-sankey.png
<a href="https://whoreportstoday.com/t/abt">Abbott Laboratories (ABT) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Comparable sales growth was 7.0%, compared with 14.5% reported.
- SG&A rose 39.8% to $4,266 million, including about $670 million to settle the Gill case and NEC claims.
- Amortization of intangible assets rose from $420 million to $841 million, and operating margin fell from 18.1% to 10.4%.
- Net interest expense rose from $44 million to $297 million.
- The GAAP tax rate was 25.3%, compared with 24.6% a year earlier, and included about $100 million of deferred tax adjustments and $35 million of net tax expense from prior-year positions.
- Excluding specified items, EPS was $1.42 compared with $1.30, and the diluted share count fell from 1,749 million to 1,738 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Robert B. FordChairman of the Board and Chief Executive Officer [1]
- Philip P. BoudreauExecutive Vice President, Finance and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Abbottsince 2008
- Chairman of the Board and Chief Executive Officersince 2021
- President and Chief Executive Officer2020–2021
- Corporate Officer2008
Source: SEC EDGAR: 10-K annual report, 2026-02-20 · as of 10/21/2026
- Abbottsince 2020
- Executive Vice President, Finance and Chief Financial Officersince 2024
- Senior Vice President, Finance and Chief Financial Officer2023–2024
- Vice President, Finance and Controller2020–2023
Source: SEC EDGAR: 10-K annual report, 2026-02-20 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Heads-up
- net income fell 44% y/y in Q3 2026
Net income for Q3 2026: $920M, −44% y/y. In the report's figures: costs grew faster than revenue: interest expense, net +575% y/y, selling, general, and administrative +40% y/y, amortization of intangible assets +100% y/y. The company explains: gross margin fell on higher intangible amortization from the Exact Sciences acquisition, higher costs and foreign exchange (Form 10-Q). Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| Q4 2026 | EPS (non-GAAP) $1.62–1.67 | revenue $11.46BEPS (GAAP) $1.01 | — |
| FY2026 | EPS (non-GAAP) $5.50–5.55 (reaffirmed) | revenue $44.3BEPS (GAAP) $3.72 | — |
How we calculate
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 21, 2026); every figure is checked against the release text.
ABT earnings history: past report dates
| Oct 21, 2026 Wed | 7:36 ambefore market open | Sep 30, 2026 | $13.0B+14% y/y | $0.53−44% y/y |
| Jul 16, 2026 Thu | 7:36 ambefore market open | Jun 30, 2026 | $12.6B+13% y/y | $0.53−48% y/y |
| Apr 16, 2026 Thu | 7:36 ambefore market open | Mar 31, 2026 | $11.2B+8% y/y | $0.61−20% y/y |
| Jan 22, 2026 Thu | 7:35 ambefore market open | Dec 31, 2025 | ≈$11.5B+4% y/y | ≈$1.01−81% y/y |
| Oct 15, 2025 Wed | 7:33 ambefore market open | Sep 30, 2025 | $11.4B+7% y/y | $0.94+0% y/y |
| Jul 17, 2025 Thu | 7:34 ambefore market open | Jun 30, 2025 | $11.1B+7% y/y | $1.01+36% y/y |
| Apr 16, 2025 Wed | 7:36 ambefore market open | Mar 31, 2025 | $10.4B+4% y/y | $0.76+9% y/y |
| Jan 22, 2025 Wed | 7:13 ambefore market open | Dec 31, 2024 | ≈$11.0B+7% y/y | ≈$5.26+478% y/y |
| Oct 16, 2024 Wed | 7:37 ambefore market open | Sep 30, 2024 | $10.6B+5% y/y | $0.94+15% y/y |
| Jul 18, 2024 Thu | 7:37 ambefore market open | Jun 30, 2024 | $10.4B+4% y/y | $0.74−5% y/y |
| Apr 17, 2024 Wed | 7:36 ambefore market open | Mar 31, 2024 | $10.0B+2% y/y | $0.70−7% y/y |
| Jan 24, 2024 Wed | 7:36 ambefore market open | Dec 31, 2023 | ≈$10.2B+1% y/y | ≈$0.91+54% y/y |
| Oct 18, 2023 Wed | 7:37 ambefore market open | Sep 30, 2023 | $10.1B−3% y/y | $0.82+1% y/y |
| Jul 20, 2023 Thu | 8:29 ambefore market open | Jun 30, 2023 | $10.0B−11% y/y | $0.78−32% y/y |
| Apr 19, 2023 Wed | 7:25 ambefore market open | Mar 31, 2023 | $9.7B−18% y/y | $0.75−45% y/y |
| Jan 25, 2023 Wed | 7:38 ambefore market open | Dec 31, 2022 | ≈$10.1B−12% y/y | ≈$0.59−47% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Abbott Laboratories: 15-year financials
| 2025 | 44,328 | 8,053 | 6,524 | 7,395 | 4,116 |
| 2024 | 41,950 | 6,825 | 13,402 | 6,351 | 3,836 |
| 2023 | 40,109 | 6,478 | 5,723 | 5,059 | 3,556 |
| 2022 | 43,653 | 8,362 | 6,933 | 7,804 | 3,309 |
| 2021 | 43,075 | 8,425 | 7,071 | 8,648 | 3,202 |
| 2020 | 34,608 | 5,357 | 4,495 | 5,724 | 2,560 |
| 2019 | 31,904 | 4,532 | 3,687 | 4,498 | 2,270 |
| 2018 | 30,578 | 3,650 | 2,368 | 4,906 | 1,974 |
| 2017 | 27,390 | 1,564 | 477 | 4,435 | 1,849 |
| 2016 | 20,853 | 3,026 | 1,400 | 2,082 | 1,539 |
| 2015 | 20,405 | 2,867 | 4,423 | 1,856 | 1,443 |
| 2014 | 20,247 | 2,599 | 2,284 | 2,598 | 1,342 |
| 2013 | 19,657 | 2,133 | 2,576 | 2,179 | 882 |
| 2012 | 19,050 | 1,360 | 5,963 | 7,519 | 3,183 |
| 2011 | 21,407 | 1,629 | 4,728 | 7,479 | 2,938 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Abbott Laboratories: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 86,713 | 52,130 | 12,929 | 8,522 | 25,996 | 16,496 |
| 2024 | 81,414 | 47,664 | 14,125 | 7,616 | 23,656 | 14,157 |
| 2023 | 73,214 | 38,603 | 14,679 | 6,896 | 22,670 | 13,841 |
| 2022 | 74,438 | 36,686 | 16,773 | 9,882 | 25,224 | 15,489 |
| 2021 | 75,196 | 35,802 | 18,050 | 9,799 | 24,239 | 13,105 |
| 2020 | 72,548 | 32,784 | 18,747 | 6,838 | 20,441 | 11,907 |
| 2019 | 67,887 | 31,088 | 18,139 | 3,860 | 15,667 | 10,863 |
| 2018 | 67,173 | 30,524 | 19,566 | 3,844 | 14,632 | 9,012 |
| 2017 | 76,250 | 30,897 | 27,924 | 9,407 | 20,147 | 8,912 |
| 2016 | 52,666 | 20,538 | 22,006 | 18,620 | 26,776 | 6,660 |
| 2015 | 41,247 | 21,211 | 9,001 | 5,001 | 14,155 | 9,186 |
| 2014 | 41,207 | 21,526 | 7,830 | 4,063 | 13,556 | 10,467 |
| 2013 | 42,937 | 25,171 | 6,561 | 3,475 | 19,247 | 9,507 |
| 2012 | 67,235 | 26,721 | 20,476 | 10,802 | 31,323 | 13,280 |
| 2011 | 60,277 | 24,440 | 15,415 | 6,813 | 23,769 | 15,480 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 5,540 | 6,251 | −711 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,198 | 1,064 | |
| · incl. stock-based comp (non-cash)share-based compensation | 622 | 551 | |
| Capexpurchases of property & equipment | −1,409 | −1,482 | +73 |
| Free cash flow ≈operating cash flow − capex | 4,131 | 4,769 | −638 |
| Investing activities, netcapex, acquisitions, securities | −21,382 | −1,509 | −19,873 |
| Financing activities, netdebt, buybacks, dividends | 11,390 | −4,912 | +16,302 |
| · incl. buybacksrepurchases of common stock | −1,236 | −591 | −645 |
| · incl. dividends paid | −3,294 | −3,086 | −208 |
| Net change in cash | −4,470 | −105 | −4,365 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $51.0B (47% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 2026Per the 2025 10-K, Abbott has a single share class (Common Shares); declared dividend of $2.40 per share vs. $2.24 a year earlier (+7.1%). sec.gov ↗
- Dec 2025Diluted shares fell 2.1% over 2020–2025; SBC of $0.66B = 1.5% of $44.3B revenue. data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Apr 2026An 8-K disclosed a settlement of the shareholder derivative suit over infant formula (In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation) — with no payout borne by shareholders. sec.gov ↗
- Feb 2026Legal Proceedings in the 2025 10-K lists no settled suits for misleading investors and no SEC cases; the DOJ is running a product investigation into infant formula. sec.gov ↗
Scoring: 2.0, no deductions: single share class, share count −2% over 5 years, SBC 1.5% of revenue, dividend raised every year; investor suit over infant formula dismissed, derivative suit settled in the company's favor
- Share classes
- Single class: Common Shares (2025 10-K cover); cumulative voting in board elections.
- Dilution
- Diluted shares −2.1% over 2020–2025 (XBRL), SBC 1.5% of revenue.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year: $2.08 → $2.24 → $2.40 over 2023–2025; quarterly payout raised to $0.63 from 02/2026 (10-K).
- Lawsuits & regulators
- The investor class action over the Sturgis plant was not settled with a payout (dismissed, per media reports) — no deduction; the derivative suit was settled (2026) with a $40M capex commitment and reforms, with the company as beneficiary; the DOJ formula probe is product-related, no deduction.
- Related parties
- Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Abbott Laboratories (ABT) earnings: FAQ
When is ABT's next earnings date?
We have not yet seen an announcement of the date from Abbott Laboratories (ABT). Based on last year's report on Jan 22, 2026, the next report is expected around Jan 21, 2027.
What time does ABT report earnings?
Abbott Laboratories usually reports before market open: its latest results release was filed with the SEC at 7:36 am ET on Oct 21, 2026.
When did ABT last report earnings?
Abbott Laboratories reported Q3 2026 results on Oct 21, 2026.
What has Abbott Laboratories guided for Q4 2026?
Company guidance for Q4 2026: EPS (non-GAAP) $1.62–1.67. A year ago (Q4 2025): revenue $11.46B, EPS (GAAP) $1.01. Company guidance for FY2026: EPS (non-GAAP) $5.50–5.55 (reaffirmed). A year ago (FY2025): revenue $44.3B, EPS (GAAP) $3.72. Source: the company's earnings release (Form 8-K filed Oct 21, 2026).
Where can I find Abbott Laboratories's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABT's filings; this page breaks the latest report down in a Sankey chart.
What was ABT's net income in Q3 2026?
Abbott Laboratories reported net income of $920M for Q3 2026 (−44.0% year over year), under US GAAP.
Does Abbott Laboratories pay dividends?
Yes. In 2025, Abbott Laboratories paid $4,116M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Abbott Laboratories's revenue changed since 2011?
Per its 10-K filings, revenue grew 2.1x: $21,407M in 2011 and $44,328M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · all reports